The three Sopharma AD factories - the one in Kazanlak, the Tablet production and Ampoule production in Sofia - have Nivalin in common, one of the strongest Sopharma products. Nivalin is sold in more than 10 countries outside Bulgaria, making it one of the most famous Sopharma products. It increases the intensity of the reflex centers of the spinal cord, medulla oblongata and cerebral cortex, thus influences all links of the reflex arc.
Sofia, Bulgaria January 20, 2025 – According to the requirements of Art. 100t of the Law on Public Offering of Securities (LPOS), “Sopharma” AD (SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) notifies, that for December 2024 the Company recorded an increase in sales of 55% compared to the same month of the previous year, incl. 29% increase in domestic sales and 77% increase in export sales.
For the period from the beginning of 2024, the Company recorded a decrease in sales of 5%, incl. 5% increase of domestic sales and 11% decrease in export sales.
Sofia, Bulgaria, January 15, 2025 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that in pursuance of a decision of the Board of Directors of SOPHARMA AD from October 14, 2024 and based on art. 195 and art. 196 of the Commercial Law (CL), art. 113, para. 2, item 2 of Law on public offering of securities (LPOS) and art.
Notification from Ognian Donev in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD as of 27 December 2024
Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD as of 27 December 2024
Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD as of 20 December 2024
Notification from Ognian Donev in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD as of 20 December 2024
